EUCTR2005-006083-57-ES进行中（未招募）不适用
Estudio Multicéntrico, abierto y en fase II con Ipilimumab ( MDX-010) como extensión de tratamiento en monoterapia o seguimiento para pacientes previamente incluidos en Protocolos/Estudios con Ipilimumab ( MDX-010).Protocolo revisado 08, que incorpora las Cartas Administrativas 01 y 02 y las enmiendas 01,04,05,06,07,08,09, y 10 ( v.10.0 del 10 de septiembre de 2009)A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) ProtocolsRevised Protocol 08, incorporating Administrative Letter 01, 02, Amendments 01, 04, 05, 06, 07, 08, 09 and 10 (version 10.0, dated 10-Sep-09)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients eligible for this study must represent one of the three patient populations described in Section 3.2 of the Protocol and meet the inclusion/exclusion criteria detailed below.
- •Group C (except Group C Survival Follow-Up Only) patients must meet Inclusion Criteria 1, 2, and 3 and Exclusion Criteria 1 and 2.
- •Group C Survival Follow-Up Only patients must meet Inclusion Criteria 1, 2, 3 and Exclusion Criterion 2.
- •1. Willing and able to give written informed consent;
- •Target population
- •2. Diagnosis of advanced melanoma;
- •3. Prior treatment in one of the following studies: CA184008, CA184-022, CA184007, CA184004, MDX010-08 or MDX010-15; and meets criteria for Group A, B or C (see
- •Section 3.2.)
- •4. Accessible for treatment and Follow-Up;
- •5. All patients entering the study as Group A to receive Re-Induction must have their case discussed with a BMS Medical Monitor prior to enrollment in the companion study;
- •6. Patients who have not experienced IBE related to ipilimumab, or patients who have
- •experienced a select IBE related to ipilimumab that has completely resolved with
- •immunosuppressive therapy or controlled with hormone therapy (* see below for
- •IBEs eligible for consideration, also refer to Section 3.2.2 for definition of select
- •reversible IBEs):
- •* List of IBEs eligible for consideration:
- •a) Reversible autoimmune hepatitis
- •b) Medically manageable endocrinopathy
- •c) Reversible dermatological toxicity
- •7. Have the complete set of baseline (i.e., Screening) images of lesions and radiographic images, including, but not limited to: brain, chest, abdomen pelvis and bone scans (bone scan only as applicable). All images must be of adequate quality;
- •8. Life expectancy =16 weeks;
- •9. ECOG performance status of 0 or 1 (Group A patients only, refer to Appendix 3);
- •10. Required values for initial laboratory tests (Group A patients only):
- •WBC = 2000/uL
- •ANC = 1000/uL
- •Platelets = 50 x 10³/uL
- •Hemoglobin = 8 g/dL
- •Creatinine = 3.0 x ULN
- •AST/ALT = 2.5 x ULN for patients without liver metastasis ; = 5 x ULN for patients with liver metastasis
- •Bilirubin = 3.0 x ULN, (except patients with Gilbert’s Syndrome, who must have a total bilirubin less than 3.0 mg/dL);
- •11. No active or chronic infection with HIV, Hepatitis B or Hepatitis C;
- •Age and Sex
- •12. Men and women =18 years of age (or, = 16, if allowable per local regulatory authority);
- •Women of childbearing potential (WOCBP) must be using an adequate method of
- •contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last
- •date of study treatment in such a manner that the risk of pregnancy is minimized.
- •WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For Group A, B, and C patients:
- •1) Prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonist, except for ipilimumab;
- •2) Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled in this study.
- •For Group A and Group B patients:
- •Sex and Reproductive Status
- •3) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study;
- •4) Women who are pregnant or breastfeeding;
- •5) Women with a positive pregnancy test on enrollment or prior to study drug administration;
- •6) Sexually active fertile men whose partners are WOCBP, unless using an adequate method of birth control;
- •Target Disease Exceptions
- •7) Primary ocular melanoma;
- •Medical History and Concurrent Diseases
- •8) Any underlying medical or psychiatric condition or acute infection, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of AEs (such as a condition associated with frequent diarrhea) or efficacy data (such as active lung infection that interferes with response assessments);
- •8a) Autoimmune disease: subjects with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease are excluded from this study as are subjects with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [eg, Wegener’s Granulomatosis]). Subjects with motor neuropathy considered of autoimmune origin (eg, Guillain-Barré Syndrome) are excluded from this study.
- •Prohibited Therapies and/or Medications
- •9) Concomitant therapy with any anti-cancer agent (for up to 30 days prior to 1st dose of ipilimumab in this study and except as defined in Section 6.2.8.5), immunosuppressive agents (for up to 30 days prior to 1st dose of ipilimumab in this study), surgery or radiotherapy (except as defined in Sections 6.2.8.3 and 6.2.8.4) (for up to 30 days prior to 1st dose of ipilimumab in this study); and chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses and for up to 30 days prior to 1st dose of ipilimumab in this study).
- •10) Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 4 weeks prior to or after any dose of ipilimumab);
- •11) Treatment with other investigational products within the last 4 weeks prior to or during this study.
研究者
相似试验
进行中（未招募）
不适用
Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adultoEUCTR2005-001709-24-ESGrupo Español de Investigación en Sarcomas (GEIS)
进行中（未招募）
不适用
Estudio fase II, multicéntrico, abierto, para comparar la eficacia y seguridad de RAD001 en primera línea seguido de sunitinib en segunda línea frente a sunitinib en primera línea seguido de RAD001 en segunda línea en el tratamiento de pacientes con carcinoma de células renales metastásicoCarcinoma de células renalesMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2009-011056-21-ESovartis Farmacéutica, S.A427
进行中（未招募）
不适用
Estudio fase II, multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia y la seguridad de AUY922 en combinación con la terapia estándar, trastuzumab, como tratamiento de segunda línea en pacientes con cáncer gástrico avanzado HER2 positivoPacientes con cáncer gástrico avanzado HER2 positivo documentado, que progresen después de observarse beneficio clínico con el tratamiento de 1ª línea con un tratamiento que contenga trastuzumab. El beneficio clínico se define como respuesta global o enfermedad estable de por lo menos 12 semanas de duración, desde el inicio de la terapia de 1ª línea con trastuzumab según RECIST.MedDRA version: 14.0Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-ESovartis Farmaceutica S.A.48
进行中（未招募）
1 期
Estudio de fase 2, multicéntrico, en abierto, para evaluar la seguridad y la eficacia del IMC-1121B en combinación con 5-FU/AF y oxaliplatino (FOLFOX-6 modificado) como tratamiento de primera línea en pacientes con cáncer colorrectal metastásico.An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination with 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients with Metastatic Colorectal Cancer.Cáncer colorrectal metastásicoMetastatic Colorectal CancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004936-19-ESImClone Systems Incorporated45
进行中（未招募）
不适用
Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y refractario a la quimioterapia basada en irinotecán.Open, multicenter phase II study to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy - SPECTRACáncer colorrectal metastástasico KRAS no mutado y refractarios a la quimioterápia basada en irinotecánEUCTR2009-010833-27-ESGrupo de Tratamiento de los Tumores Digestivos - TTD